{"id":1436,"date":"2022-11-15T10:50:22","date_gmt":"2022-11-15T16:50:22","guid":{"rendered":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/?p=1436"},"modified":"2022-12-13T11:21:34","modified_gmt":"2022-12-13T17:21:34","slug":"rsv-antibody-from-sanofi-and-astrazeneca-approved-in-europe","status":"publish","type":"post","link":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/2022\/11\/15\/rsv-antibody-from-sanofi-and-astrazeneca-approved-in-europe\/","title":{"rendered":"RSV antibody from Sanofi and AstraZeneca approved in Europe"},"content":{"rendered":"<div class=\"panel body-content\"><div class=\"panel__container\">\n<p>(<a href=\"https:\/\/cen.acs.org\/business\/RSV-antibody-Sanofi-AstraZeneca-approved\/100\/i40\">Chemical and Engineering New<\/a>s) With the first vaccines to guard against respiratory syncytial virus (RSV) expected to receive regulatory approval in the months ahead, the European Commission earlier this month gave its nod to a monoclonal antibody developed by Sanofi and AstraZeneca to prevent RSV lower respiratory tract illness (LRTI) in newborns and infants. The EC\u2019s approval of the drug, Beyfortus (nirsevimab), is based on a series of clinical trials, including Phase 3 trials, and follows the recommendation in September of the European Medicines Agency\u2019s Committee for Medicinal Products for Human Use.<\/p>\n<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>(Chemical and Engineering News) With the first vaccines to guard against respiratory syncytial virus (RSV) expected to receive regulatory approval in the months ahead, the European Commission earlier this month gave its nod to a monoclonal antibody developed by Sanofi and AstraZeneca to prevent RSV lower respiratory tract illness (LRTI) in newborns and infants. The [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[47],"tags":[],"class_list":["post-1436","post","type-post","status-publish","format-standard","hentry","category-rsv-therapies"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/posts\/1436","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/comments?post=1436"}],"version-history":[{"count":1,"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/posts\/1436\/revisions"}],"predecessor-version":[{"id":1437,"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/posts\/1436\/revisions\/1437"}],"wp:attachment":[{"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/media?parent=1436"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/categories?post=1436"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/tags?post=1436"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}